Amarin fishes for another CFO as downsizing takes hold; CureVac makes a deal, then lines up Novartis exec to lead development
→ Mired in flagging sales for Vascepa, the harsh realities of the current climate in biotech have hit Amarin as they slice 40% of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
